tetano
Editor, Senior Moderator
Cell
. 2022 Jan 4;S0092-8674(21)01578-6.
doi: 10.1016/j.cell.2021.12.046. Online ahead of print.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai[SUP] 1 [/SUP], Jiandong Huo[SUP] 2 [/SUP], Daming Zhou[SUP] 3 [/SUP], Jiří Zahradník[SUP] 4 [/SUP], Piyada Supasa[SUP] 1 [/SUP], Chang Liu[SUP] 5 [/SUP], Helen M E Duyvesteyn[SUP] 2 [/SUP], Helen M Ginn[SUP] 6 [/SUP], Alexander J Mentzer[SUP] 7 [/SUP], Aekkachai Tuekprakhon[SUP] 1 [/SUP], Rungtiwa Nutalai[SUP] 1 [/SUP], Beibei Wang[SUP] 1 [/SUP], Aiste Dijokaite[SUP] 1 [/SUP], Suman Khan[SUP] 4 [/SUP], Ori Avinoam[SUP] 4 [/SUP], Mohammad Bahar[SUP] 2 [/SUP], Donal Skelly[SUP] 8 [/SUP], Sandra Adele[SUP] 9 [/SUP], Sile Ann Johnson[SUP] 9 [/SUP], Ali Amini[SUP] 10 [/SUP], Thomas G Ritter[SUP] 11 [/SUP], Chris Mason[SUP] 11 [/SUP], Christina Dold[SUP] 12 [/SUP], Daniel Pan[SUP] 13 [/SUP], Sara Assadi[SUP] 14 [/SUP], Adam Bellass[SUP] 14 [/SUP], Nicola Omo-Dare[SUP] 14 [/SUP], David Koeckerling[SUP] 15 [/SUP], Amy Flaxman[SUP] 16 [/SUP], Daniel Jenkin[SUP] 16 [/SUP], Parvinder K Aley[SUP] 17 [/SUP], Merryn Voysey[SUP] 17 [/SUP], Sue Ann Costa Clemens[SUP] 18 [/SUP], Felipe Gomes Naveca[SUP] 19 [/SUP], Valdinete Nascimento[SUP] 19 [/SUP], Fernanda Nascimento[SUP] 19 [/SUP], Cristiano Fernandes da Costa[SUP] 20 [/SUP], Paola Cristina Resende[SUP] 21 [/SUP], Alex Pauvolid-Correa[SUP] 22 [/SUP], Marilda M Siqueira[SUP] 21 [/SUP], Vicky Baillie[SUP] 23 [/SUP], Natali Serafin[SUP] 23 [/SUP], Gaurav Kwatra[SUP] 23 [/SUP], Kelly Da Silva[SUP] 23 [/SUP], Shabir A Madhi[SUP] 23 [/SUP], Marta C Nunes[SUP] 23 [/SUP], Tariq Malik[SUP] 24 [/SUP], Peter J M Openshaw[SUP] 25 [/SUP], J Kenneth Baillie[SUP] 26 [/SUP], Malcolm G Semple[SUP] 27 [/SUP], Alain R Townsend[SUP] 28 [/SUP], Kuan-Ying A Huang[SUP] 29 [/SUP], Tiong Kit Tan[SUP] 30 [/SUP], Miles W Carroll[SUP] 31 [/SUP], Paul Klenerman[SUP] 32 [/SUP], Eleanor Barnes[SUP] 32 [/SUP], Susanna J Dunachie[SUP] 33 [/SUP], Bede Constantinides[SUP] 34 [/SUP], Hermione Webster[SUP] 34 [/SUP], Derrick Crook[SUP] 34 [/SUP], Andrew J Pollard[SUP] 12 [/SUP], Teresa Lambe[SUP] 35 [/SUP], OPTIC Consortium; ISARIC4C Consortium; Neil G Paterson[SUP] 6 [/SUP], Mark A Williams[SUP] 6 [/SUP], David R Hall[SUP] 6 [/SUP], Elizabeth E Fry[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 36 [/SUP], Jingshan Ren[SUP] 37 [/SUP], Gideon Schreiber[SUP] 38 [/SUP], David I Stuart[SUP] 39 [/SUP], Gavin R Screaton[SUP] 40 [/SUP]
Collaborators, Affiliations
Abstract
On 24[SUP]th[/SUP] November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Keywords: Omicron; RBD; SARS-CoV-2; Spike; immune evasion; receptor interaction; vaccines; variants.
. 2022 Jan 4;S0092-8674(21)01578-6.
doi: 10.1016/j.cell.2021.12.046. Online ahead of print.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai[SUP] 1 [/SUP], Jiandong Huo[SUP] 2 [/SUP], Daming Zhou[SUP] 3 [/SUP], Jiří Zahradník[SUP] 4 [/SUP], Piyada Supasa[SUP] 1 [/SUP], Chang Liu[SUP] 5 [/SUP], Helen M E Duyvesteyn[SUP] 2 [/SUP], Helen M Ginn[SUP] 6 [/SUP], Alexander J Mentzer[SUP] 7 [/SUP], Aekkachai Tuekprakhon[SUP] 1 [/SUP], Rungtiwa Nutalai[SUP] 1 [/SUP], Beibei Wang[SUP] 1 [/SUP], Aiste Dijokaite[SUP] 1 [/SUP], Suman Khan[SUP] 4 [/SUP], Ori Avinoam[SUP] 4 [/SUP], Mohammad Bahar[SUP] 2 [/SUP], Donal Skelly[SUP] 8 [/SUP], Sandra Adele[SUP] 9 [/SUP], Sile Ann Johnson[SUP] 9 [/SUP], Ali Amini[SUP] 10 [/SUP], Thomas G Ritter[SUP] 11 [/SUP], Chris Mason[SUP] 11 [/SUP], Christina Dold[SUP] 12 [/SUP], Daniel Pan[SUP] 13 [/SUP], Sara Assadi[SUP] 14 [/SUP], Adam Bellass[SUP] 14 [/SUP], Nicola Omo-Dare[SUP] 14 [/SUP], David Koeckerling[SUP] 15 [/SUP], Amy Flaxman[SUP] 16 [/SUP], Daniel Jenkin[SUP] 16 [/SUP], Parvinder K Aley[SUP] 17 [/SUP], Merryn Voysey[SUP] 17 [/SUP], Sue Ann Costa Clemens[SUP] 18 [/SUP], Felipe Gomes Naveca[SUP] 19 [/SUP], Valdinete Nascimento[SUP] 19 [/SUP], Fernanda Nascimento[SUP] 19 [/SUP], Cristiano Fernandes da Costa[SUP] 20 [/SUP], Paola Cristina Resende[SUP] 21 [/SUP], Alex Pauvolid-Correa[SUP] 22 [/SUP], Marilda M Siqueira[SUP] 21 [/SUP], Vicky Baillie[SUP] 23 [/SUP], Natali Serafin[SUP] 23 [/SUP], Gaurav Kwatra[SUP] 23 [/SUP], Kelly Da Silva[SUP] 23 [/SUP], Shabir A Madhi[SUP] 23 [/SUP], Marta C Nunes[SUP] 23 [/SUP], Tariq Malik[SUP] 24 [/SUP], Peter J M Openshaw[SUP] 25 [/SUP], J Kenneth Baillie[SUP] 26 [/SUP], Malcolm G Semple[SUP] 27 [/SUP], Alain R Townsend[SUP] 28 [/SUP], Kuan-Ying A Huang[SUP] 29 [/SUP], Tiong Kit Tan[SUP] 30 [/SUP], Miles W Carroll[SUP] 31 [/SUP], Paul Klenerman[SUP] 32 [/SUP], Eleanor Barnes[SUP] 32 [/SUP], Susanna J Dunachie[SUP] 33 [/SUP], Bede Constantinides[SUP] 34 [/SUP], Hermione Webster[SUP] 34 [/SUP], Derrick Crook[SUP] 34 [/SUP], Andrew J Pollard[SUP] 12 [/SUP], Teresa Lambe[SUP] 35 [/SUP], OPTIC Consortium; ISARIC4C Consortium; Neil G Paterson[SUP] 6 [/SUP], Mark A Williams[SUP] 6 [/SUP], David R Hall[SUP] 6 [/SUP], Elizabeth E Fry[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 36 [/SUP], Jingshan Ren[SUP] 37 [/SUP], Gideon Schreiber[SUP] 38 [/SUP], David I Stuart[SUP] 39 [/SUP], Gavin R Screaton[SUP] 40 [/SUP]
Collaborators, Affiliations
- PMID: 35081335
- DOI: 10.1016/j.cell.2021.12.046
Abstract
On 24[SUP]th[/SUP] November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Keywords: Omicron; RBD; SARS-CoV-2; Spike; immune evasion; receptor interaction; vaccines; variants.